NP_002380.3
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
membrane cofactor protein isoform 1
NCBI Official Synonym Full Names
CD46 molecule, complement regulatory protein
NCBI Official Synonym Symbols
MCP; TLX; AHUS2; MIC10; TRA2.10 [Similar Products]
NCBI Protein Information
membrane cofactor protein
UniProt Protein Name
Membrane cofactor protein
UniProt Synonym Protein Names
TLX; Trophoblast leukocyte common antigen; CD_antigen: CD46
UniProt Synonym Gene Names
UniProt Entry Name
MCP_HUMAN
NCBI Summary for CD46
The protein encoded by this gene is a type I membrane protein and is a regulatory part of the complement system. The encoded protein has cofactor activity for inactivation of complement components C3b and C4b by serum factor I, which protects the host cell from damage by complement. In addition, the encoded protein can act as a receptor for the Edmonston strain of measles virus, human herpesvirus-6, and type IV pili of pathogenic Neisseria. Finally, the protein encoded by this gene may be involved in the fusion of the spermatozoa with the oocyte during fertilization. Mutations at this locus have been associated with susceptibility to hemolytic uremic syndrome. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jun 2010]
UniProt Comments for CD46
CD46: Acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement- mediated injury by cleaving C3b and C4b deposited on host tissue. May be involved in the fusion of the spermatozoa with the oocyte during fertilization. Also acts as a costimulatory factor for T- cells which induces the differentiation of CD4+ into T-regulatory 1 cells. T-regulatory 1 cells suppress immune responses by secreting interleukin-10, and therefore are thought to prevent autoimmunity. A number of viral and bacterial pathogens seem to exploit this property and directly induce an immunosuppressive phenotype in T-cells by binding to CD46. Defects in CD46 are a cause of susceptibility to hemolytic uremic syndrome atypical type 2 (AHUS2). An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Patients with CD46 mutations seem to have an overall better prognosis compared to patients carrying CFH mutations. 16 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral; Cell surface; Receptor, misc.
Chromosomal Location of Human Ortholog: 1q32
Cellular Component: Golgi apparatus; inner acrosomal membrane; focal adhesion; cell surface; basolateral plasma membrane; integral to plasma membrane; plasma membrane
Molecular Function: enzyme inhibitor activity; complement binding; protein binding; cadherin binding; endopeptidase activity; receptor activity
Biological Process: positive regulation of memory T cell differentiation; adaptive immune response; positive regulation of regulatory T cell differentiation; viral reproduction; T cell mediated immunity; proteolysis; positive regulation of interleukin-10 production; regulation of Notch signaling pathway; negative regulation of complement activation; single fertilization; negative regulation of catalytic activity; regulation of complement activation; interleukin-10 production; innate immune response; positive regulation of T cell proliferation; complement activation, classical pathway
Product References and Citations for anti-CD46 antibody
Weyand, N.J., et al. J. Immunol. 184(2):694-701(2010) Santiago, C., et al. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 66 (PT 1), 91-94 (2010) Sullivan, M., et al. Ann. Hum. Genet. 74(1):17-26(2010) Lee, S.W., et al. J. Cell Biol. 156(6):951-957(2002)
Research Articles on CD46
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Pathways associated with anti-CD46 antibody
Diseases associated with anti-CD46 antibody
Organs/Tissues associated with anti-CD46 antibody
|